NEW YORK CITY, NY / ACCESS Newswire / February 27, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novo Nordisk A/S ("Novo" or "the Company") (NYSE:NVO). Investors who purchased Novo securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/NVO.
Novo Investigation Details
On February 23, 2026, CNBC published a report titled: "Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly’s in trial." According to the report, the Company’s "experimental drug, CagriSema, didn’t achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to Eli Lilly’s rival drug tirzepatide after 84 weeks, Novo said in a statement Monday morning." Following this news, Novo stock dropped more than 15% in premarket trading.
What’s Next for Novo Investors?
If you are aware of any facts relating to this investigation or purchased Novo securities, you can assist this investigation by visiting the firm’s site: bgandg.com/NVO. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Novo Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Novo Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com
Attorney advertising.
Prior results do not guarantee similar outcomes.
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS Newswire
COMTEX_474340215/2457/2026-02-27T11:01:21